Several potential biomarkers have been recently described such as a three-protein panel in urine [11], Galectin-1 (Gal-1) in serum [12], thrombospondin-2 (THBS2) in plasma [13], circulating tumor DNA (ctDNA) [14], and the IMMrayTM PanCan-d 29 biomarker signature in serum [15]. The gene discussed is LGALS1; the disease is neoplasm.